CUK.L Share News (CUK)

Experian may sit in the support services sector but its share price - up 80 per cent from last year's low - makes it look more like a bank. At 493p, up 7p, or 12 times current-year earnings, the shares have begun to price in recovery but should advance further as economic signals improve. Buy on weakness, says the Times.Those looking for a solid investment, a strong dividend and the potential for share price growth, look no further than Britvic, the FTSE 250-listed soft drinks company that makes Tango and Robinsons squash, and which has the licence to sell Pepsi in the UK. Perhaps the only fly in the ointment is that the UBS experts have a 12-month price target of just 280p. The Independent thinks they will have to revise that soon, however, and would be at the front of the queue to buy the shares. Buy.Cape says it has significant headroom within its banking covenants and the Telegraph's Questor expects further progress on debt this year. The shares remain a buy, but its shares should be regarded as a speculative buy and not one on which to bet the farm.The conventional wisdom is that parents are never likely to stop spending money on their children, even in a recession. Yesterday's final results from the children's goods retailer Mothercare underlined that argument, even if the company would claim that it is being proactive in ensuring it more than survives the downturn. At its current level, the share price is at an attractive entry point. Buy, says the Independent.The returns on cash on deposit are paltry; the returns on printers of cash are somewhat better. At least, that is true in the case of De La Rue, the FTSE 250 banknote specialist, which, having handed back £460 million to shareholders last year after the sale of its cash systems division, yesterday declared an above-forecast 92 per cent rise in its full-year dividend. At 908½p, or 12 times current-year earnings, and yielding 4.5 per cent, the shares should be locked away by long-term investors. Buy, says the Times.Care UK is a clear beneficiary of healthcare reforms that support increased private provision, as well as gaining from pressure on public finances, which should spur greater outsourcing. However, the outside risk of more contract setbacks instils caution. At 305p, or ten times earnings on Brewin Dolphin's estimates, avoid, says the Times.GW Pharmaceuticals posted its maiden profit as part of its interim results, which also confirmed the news of a few weeks ago that Sativex, its cannabis-based multiple sclerosis treatment, had passed all-important final phase drug trials. Hindsight is a wonderful thing, and of course investors would have been better buying the shares three months ago. However, they are still worth buying, according to the Independent.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.